Clinical Trial Results:
A randomised controlled, open label, phase II pilot study comparing the toxicity of rituximab plus CHOP chemotherapy with rituximab plus CHOP chemotherapy and bortezomib in adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) being treated in haemato-oncology units within South East Wales
Summary
|
|
EudraCT number |
2006-003333-33 |
Trial protocol |
GB |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
23 Jun 2022
|
First version publication date |
23 Jun 2022
|
Other versions |
|
Summary report(s) |
Early termination letter |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.